PAION

About PAION

PAION is a biopharmaceutical company headquartered in Aachen, Germany and has a second site in Cambridge, UK. The company is specialized in developing and commercializing innovative drugs for the hospital-based treatment in indications for which there is a substantial unmet medical need. PAION has a “Search & Develop” business model, which is based on its core expertise in drug development. Where appropriate, particularly during the late stages of the clinical development, PAION seeks to collaborate with experienced partners. PAION’s near-term value drivers are CNS 7056, an ultra-short acting anesthetic/sedative with disruptive market potential in phase II for procedural anesthesia, M6G, a short-term, low risk opportunity in acute pain care with superior side effect profile to morphine and Desmoteplase, a partnered and fully-funded phase III asset with estimated peak sales potential of US$600 million.

About the speaker
Dr. Wolfgang Söhngen, is chairman of PAION AG’s management board and co-founder of both PAION AG and PAION Deutschland GmbH.

Prior to founding Paion GmbH, he was employed by Grünenthal GmbH (1987), where his tasks included clinical development, project management, corporate development and strategic planning. During that time, he has established numerous contacts in the industry that were of further use to him after leaving Grünenthal GmbH, when founding his own consulting firm (Virtueality) in 1997, which specialized in healthcare. He serves as a Managing Director of PAION Deutschland GmbH since 2000 and as CEO of PAION AG since 2004.

He is responsible for the areas of investor relations, business development and strategic planning.